Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
170 hedge funds and large institutions have $2.62B invested in Juno Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 70 increasing their positions, 39 reducing their positions, and 18 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 39
78% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 18
61% more call options, than puts
Call options by funds: $52.4M | Put options by funds: $32.5M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
11% more capital invested
Capital invested by funds: $2.35B → $2.62B (+$270M)
8% more funds holding
Funds holding: 158 → 170 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.4M |
| 2 |
RCM
Riverhead Capital Management
Wilmington,
Delaware
|
+$26.6M |
| 3 |
BCM
Biomark Capital Management
Greenwich,
Connecticut
|
+$25M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$19.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$19.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.9M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$8.06M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$6.92M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.95M |
| 5 |
Morgan Stanley
New York
|
-$4.38M |
JUNO Hedge Fund Activity: Q2 2016 in Review
170 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q2 2016, worth a combined $2.62B — up 11% from $2.35B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new JUNO positions and 18 closed out — a net gain of 14 holders — while 70 added to existing stakes and 39 trimmed.
The largest buyer was Vanguard Group, adding an estimated $29.4M. The largest seller was Millennium Management, exiting entirely with an estimated $9.9M sold.
- 170 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q2 2016, up from 158 in Q1 2016.
- Funds reported $2.62B of Juno Therapeutics, Inc. stock for Q2 2016, up 11% quarter-over-quarter.
- 32 funds opened new Juno Therapeutics, Inc. positions in Q2 2016 and 18 closed out, a net change of +14 holders.
- The largest Juno Therapeutics, Inc. buyer in Q2 2016 was Vanguard Group, an estimated $29.4M added.
- The largest Juno Therapeutics, Inc. seller in Q2 2016 was Millennium Management, an estimated $9.9M sold.
Based on aggregated 13F filings for Q2 2016.